The CSO of Endocyte is Exercising Options


Today it was reported that the CSO of Endocyte (ECYT), Philip Low, exercised options to buy 140,214 ECYT shares at $5.52 a share, for a total transaction value of $774.2K.

This recent transaction increases Philip Low’s holding in the company by 68.68% to a total of $13 million. Following Philip Low’s last ECYT Buy transaction on November 14, 2017, the stock climbed by 19.2%.

See today’s analyst top recommended stocks >>

Based on Endocyte’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $85.86K and GAAP net loss of $12.61 million. In comparison, last year the company earned revenue of $32.5K and had a GAAP net loss of $23.27 million. Currently, Endocyte has an average volume of 2.26M.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts